Declared Dividend • Jul 13
Dividend of CN¥0.20 announced Dividend of CN¥0.20 is the same as last year. Ex-date: 15th July 2026 Payment date: 15th July 2026 Dividend yield will be 0.5%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 46 years, indicating a lack of growth and stability in payments. Duyuru • Jun 30
ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026 ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026 Reported Earnings • Apr 28
Full year 2025 earnings released: CN¥0.079 loss per share (vs CN¥0.18 loss in FY 2024) Full year 2025 results: CN¥0.079 loss per share (improved from CN¥0.18 loss in FY 2024). Revenue: CN¥406.4m (up 22% from FY 2024). Net loss: CN¥11.9m (loss narrowed 58% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. Duyuru • Apr 28
ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026 ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China Duyuru • Mar 31
ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026 ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 New Risk • Mar 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 44% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change). Duyuru • Dec 31
ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026 ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026 Board Change • Dec 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Yongzhou Hu was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Nov 12
Chengda Pharmaceuticals Co., Ltd. Approves Board Appointments ChengDa Pharmaceuticals Co., Ltd. approved the appointment of Hu Yongzhou, independent director, Jiang Lin, independent director, Zhou Junming, independent director. Reported Earnings • Oct 28
Third quarter 2025 earnings released: EPS: CN¥0.026 (vs CN¥0.10 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.026 (down from CN¥0.10 in 3Q 2024). Revenue: CN¥102.6m (up 29% from 3Q 2024). Net income: CN¥3.95m (down 74% from 3Q 2024). Profit margin: 3.8% (down from 19% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. Duyuru • Sep 30
ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025 ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025 New Risk • Sep 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 39% per year over the past 5 years. Reported Earnings • Aug 26
Second quarter 2025 earnings released: EPS: CN¥0.094 (vs CN¥0.043 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.094 (up from CN¥0.043 in 2Q 2024). Revenue: CN¥106.1m (up 68% from 2Q 2024). Net income: CN¥14.2m (up 118% from 2Q 2024). Profit margin: 13% (up from 10% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. Declared Dividend • Jul 07
Dividend of CN¥0.20 announced Dividend of CN¥0.20 is the same as last year. Ex-date: 10th July 2025 Payment date: 10th July 2025 Dividend yield will be 0.9%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. Duyuru • Jul 02
ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025 ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025 New Risk • May 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 33% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change). New Risk • May 16
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 33% per year over the past 5 years. Reported Earnings • Apr 25
First quarter 2025 earnings released: CN¥0.009 loss per share (vs CN¥0.12 profit in 1Q 2024) First quarter 2025 results: CN¥0.009 loss per share (down from CN¥0.12 profit in 1Q 2024). Revenue: CN¥76.3m (down 24% from 1Q 2024). Net loss: CN¥1.40m (down 108% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. Duyuru • Apr 25
ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025 ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.7% per year over the past 5 years. High level of non-cash earnings (27% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.6% average weekly change). Valuation Update With 7 Day Price Move • Apr 01
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to CN¥24.29, the stock trades at a trailing P/E ratio of 52.4x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 57% over the past three years. Duyuru • Mar 31
ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025 ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 Duyuru • Dec 31
ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025 ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025 Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.21 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.21 in 3Q 2023). Revenue: CN¥79.8m (down 15% from 3Q 2023). Net income: CN¥15.2m (down 52% from 3Q 2023). Profit margin: 19% (down from 34% in 3Q 2023). The decrease in margin was primarily driven by lower revenue. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥20.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total loss to shareholders of 19% over the past year. Duyuru • Sep 30
ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024 ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to CN¥21.80, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 14% over the past year. Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.063 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.063 in 2Q 2023). Revenue: CN¥63.1m (down 2.0% from 2Q 2023). Net income: CN¥6.53m (down 33% from 2Q 2023). Profit margin: 10% (down from 15% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Declared Dividend • Jul 05
Dividend of CN¥0.20 announced Shareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Duyuru • Jun 29
ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024 ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 New Risk • May 17
New major risk - Revenue and earnings growth Earnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.4% average weekly change). Reported Earnings • Apr 22
First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 1Q 2023). Revenue: CN¥100.9m (down 1.3% from 1Q 2023). Net income: CN¥18.6m (down 5.1% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023). Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥17.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 38% over the past year. Duyuru • Mar 30
ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 22, 2024 ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2024 results on Apr 22, 2024 Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥22.92, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total loss to shareholders of 27% over the past year. Buy Or Sell Opportunity • Feb 23
Now 22% overvalued Over the last 90 days, the stock has fallen 31% to CN¥19.33. The fair value is estimated to be CN¥15.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 29%. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥17.62, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. Total loss to shareholders of 48% over the past year. Duyuru • Dec 30
ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024 ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2023 results on Apr 22, 2024 Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥27.63, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 24% over the past year. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.21 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥93.7m (up 5.9% from 3Q 2022). Net income: CN¥31.8m (up 18% from 3Q 2022). Profit margin: 34% (up from 31% in 3Q 2022). Duyuru • Sep 30
ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023 ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023 Reported Earnings • Aug 23
Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.25 (in line with 2Q 2022). Revenue: CN¥64.4m (down 41% from 2Q 2022). Net income: CN¥9.71m (down 75% from 2Q 2022). Profit margin: 15% (down from 36% in 2Q 2022). The decrease in margin was driven by lower revenue. Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥24.43, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 36% over the past year. Valuation Update With 7 Day Price Move • Jul 06
Investor sentiment deteriorates as stock falls 36% After last week's 36% share price decline to CN¥26.09, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total loss to shareholders of 65% over the past year. Duyuru • Jul 06
ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023 ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023. Reported Earnings • Apr 24
First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.30 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.30 in 1Q 2022). Revenue: CN¥102.2m (down 5.9% from 1Q 2022). Net income: CN¥19.6m (down 25% from 1Q 2022). Profit margin: 19% (down from 24% in 1Q 2022). Reported Earnings • Oct 26
Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.27 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.28 (up from CN¥0.27 in 3Q 2021). Revenue: CN¥88.4m (down 6.6% from 3Q 2021). Net income: CN¥27.0m (up 38% from 3Q 2021). Profit margin: 31% (up from 21% in 3Q 2021). The increase in margin was driven by lower expenses. Reported Earnings • Aug 15
Second quarter 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.27 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.44 (up from CN¥0.27 in 2Q 2021). Revenue: CN¥108.6m (up 15% from 2Q 2021). Net income: CN¥38.9m (up 99% from 2Q 2021). Profit margin: 36% (up from 21% in 2Q 2021). The increase in margin was primarily driven by higher revenue. Duyuru • May 24
ChengDa Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Dividend Payable on 27 May 2022 ChengDa Pharmaceuticals Co., Ltd. announced cash dividend per 10 shares (tax included) of CNY 4.500000 for 2021. The dividend payable on 27 May 2022, with a record date of 26 May 2022. Duyuru • May 12
ChengDa Pharmaceuticals Co., Ltd. Approves Cash Dividend for 2021 ChengDa Pharmaceuticals Co., Ltd. at its annual general meeting held on 9 May 2022 approved cash dividend per 10 shares (tax included) of CNY 2.0000000 for 2021. Duyuru • Apr 20
ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend for the Year 2021 ChengDa Pharmaceuticals Co., Ltd. announced final dividend proposal of CNY 4.50000000 per 10 shares (tax included) for the year 2021. Valuation Update With 7 Day Price Move • Mar 29
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥102, the stock trades at a trailing P/E ratio of 78.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Feb 15
Investor sentiment improved over the past week After last week's 27% share price gain to CN¥91.01, the stock trades at a trailing P/E ratio of 70.1x. Average trailing P/E is 32x in the Pharmaceuticals industry in China.